Ocrelizumab
Ocrelizumab is a humanized monoclonal antibody that targets CD20 on B cells and is used as a high-efficacy immunotherapy in multiple sclerosis (MS).
Ocrelizumab is a humanized monoclonal antibody that targets CD20 on B cells and is used as a high-efficacy immunotherapy in multiple sclerosis (MS). By depleting CD20-expressing B lymphocytes, it modulates the immune processes that contribute to inflammatory demyelination and disability accumulation in MS. It is approved for relapsing forms of MS and primary progressive MS (PPMS), making it one of the major disease-modifying therapies in contemporary MS care.
Biologically, ocrelizumab is part of the anti-CD20 class of B-cell–depleting therapies. In clinical practice and research, it is often discussed alongside other MS therapies such as natalizumab (Tysabri®), particularly when comparing first-line treatment strategies for newly diagnosed people with MS. Its role has also been examined in more advanced disease settings, including PPMS and aggressive phenotypes of MS, where B-cell depletion may help stabilize disease activity.
Where the papers sit
13 papers from the last 6 months study ocrelizumab directly · updated from PubMed 13 Nov 2026
Study type 4 clinical trials · 9 observational
Themes 3 themes
-
B-Cell Depletion Monitoring
B-cell depletion is moving toward individualized monitoring of treatment response, immune recovery, and safety in multiple sclerosis. CD19/CD20 kinetics, FCGR3A genotype, IL-6, immunoglobulins, and peripheral cell counts are being linked to repopulation and outcomes. Annual MRI surveillance and pharmacokinetic-pharmacodynamic models seek to target imaging follow-up and repeat dosing more efficiently. Rituximab comparisons remain part of the evidence base, while the clinical value of these markers is still unsettled.
6 papers · 46.2%
-
Multiple Sclerosis Outcomes
Relapse, MRI activity, neurofilament light chain, and B-cell measures anchor outcome assessment across multiple sclerosis populations. Comparative work weighs natalizumab against ocrelizumab, while pregnancy and postpartum studies examine disease activity after pre-pregnancy B-cell depletion. MRI biomarkers are also being used to clarify pediatric tumefactive disease. The recurring goal is risk stratification across treatment and special populations, but the evidence does not establish one preferred therapy or biomarker.
4 papers · 30.8%
-
Progressive Multiple Sclerosis
Disability outcomes and tolerability remain the focus of ocrelizumab use in primary progressive multiple sclerosis. Benefit is assessed by 24-week confirmed disability worsening, including older people and those with advanced disease. Bodyweight-adjusted higher dosing and Gulf-region real-world follow-up extend evaluation beyond pivotal populations. The evidence supports clinical use but leaves the optimal dose and benefit in advanced disease unresolved.
3 papers · 23.1%
Papers
The 13 papers from the last 6 months that study ocrelizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
B-Cell Depletion Monitoring (6)
- Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis. Clinical pharmacokinetics · 28 Aug 2026 PMID 42663866
- Longitudinal changes in serum immunoglobulin levels and peripheral immune cell counts during ocrelizumab treatment in people with multiple sclerosis. Multiple sclerosis and related disorders · 26 Aug 2026 PMID 42648012
- Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study. BMC neurology · 21 Aug 2026 PMID 42629559
- FCGR3A Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab. Neurology(R) neuroimmunology & neuroinflammation · 11 Aug 2026 PMID 42579840
- Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis. Neurology · 29 Jul 2026 PMID 42525900
- Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. The New England journal of medicine · 1 Jul 2026 PMID 42384870
Multiple Sclerosis Outcomes (4)
- Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes. Neurology(R) neuroimmunology & neuroinflammation · 12 Nov 2026 PMID 43019492
- Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. Neurology(R) neuroimmunology & neuroinflammation · 9 Oct 2026 PMID 42854176
- Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers. Neurology · 1 Oct 2026 PMID 42821841
- Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis. Journal of medical economics · 21 Jun 2026 PMID 42323726
Progressive Multiple Sclerosis (3)
- Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients. Multiple sclerosis and related disorders · 10 Oct 2026 PMID 42858537
- Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet (London, England) · 28 May 2026 PMID 42208561
- Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet (London, England) · 28 May 2026 PMID 42208560
By study type
Clinical trials (4)
- Biomarker Synergy in Relapsing Multiple Sclerosis: Neurofilament Light Chain and B Cells in Relation to Disease Outcomes. Neurology(R) neuroimmunology & neuroinflammation · 12 Nov 2026 PMID 43019492
- Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis. The New England journal of medicine · 1 Jul 2026 PMID 42384870
- Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study. Lancet (London, England) · 28 May 2026 PMID 42208561
- Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet (London, England) · 28 May 2026 PMID 42208560
Observational studies and case reports (9)
- Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients. Multiple sclerosis and related disorders · 10 Oct 2026 PMID 42858537
- Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy. Neurology(R) neuroimmunology & neuroinflammation · 9 Oct 2026 PMID 42854176
- Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers. Neurology · 1 Oct 2026 PMID 42821841
- Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis. Clinical pharmacokinetics · 28 Aug 2026 PMID 42663866
- Longitudinal changes in serum immunoglobulin levels and peripheral immune cell counts during ocrelizumab treatment in people with multiple sclerosis. Multiple sclerosis and related disorders · 26 Aug 2026 PMID 42648012
- Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study. BMC neurology · 21 Aug 2026 PMID 42629559
- FCGR3A Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab. Neurology(R) neuroimmunology & neuroinflammation · 11 Aug 2026 PMID 42579840
- Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis. Neurology · 29 Jul 2026 PMID 42525900
- Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis. Journal of medical economics · 21 Jun 2026 PMID 42323726
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.